Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
psilocybin (Dana-Farber Cancer Institute)
- Development stage
- Unknown
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Psilocybin is a naturally occurring psychedelic compound being investigated as a synthetic small molecule prodrug for the treatment of psychological distress. In the body, psilocybin is rapidly converted to psilocin, which acts as a potent agonist at the serotonin 5-HT2A receptor. This specific intervention, led by Dr. Yvan Beaussant at the Dana-Farber Cancer Institute, involves "Psilocybin-Assisted Therapy," which combines a single 25 mg oral dose of psilocybin with a structured psychotherapy protocol consisting of preparation and integration sessions. The primary indication being studied in the PATH (Psilocybin-Assisted Therapy for Demoralization in Hospice Care) trial is demoralization syndrome in terminally ill patients receiving hospice care, aiming to reduce existential suffering and improve quality of life.
- Other names
- Psilocybin-assisted therapyPsilocybin-assisted psychotherapy4-phosphoryloxy-N,N-dimethyltryptamine
02
Targets
HTR2C (5-hydroxytryptamine 2C receptor)HTR2A (Serotonin receptor 5-HT2A)NTRK2 (Tropomyosin-related kinase receptor type B)
Beyond the preview
Go deeper on psilocybin (Dana-Farber Cancer Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on psilocybin (Dana-Farber Cancer Institute).